{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:39:59Z","timestamp":1793122799810,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtho.2026.104179","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:48:12Z","timestamp":1789350492000},"page":"104179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB\u2013IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Aokage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Laktionov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charuwan","family":"Akewanlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huu Vinh","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Armenteros-Monterroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Rukazenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.104179_bib1","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.2017.72.4401","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology\/cancer care Ontario clinical practice guideline update","volume":"35","author":"Kris","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib2","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib3","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104179_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib5","author":"Zer"},{"key":"10.1016\/j.jtho.2026.104179_bib6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","volume":"40","author":"Pisters","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib7","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/OP-24-00784","article-title":"Management of stage III non-small cell lung cancer: ASCO guideline rapid recommendation update clinical insights","volume":"21","author":"Singh","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtho.2026.104179_bib9","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1158\/1078-0432.CCR-21-1034","article-title":"FDA approval summary: osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review","volume":"27","author":"Koch","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.104179_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.104179_bib12","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib13","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104179_bib15","article-title":"Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation","volume":"5","author":"Occhipinti","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2026.104179_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12957-023-02925-x","article-title":"Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials","volume":"21","author":"Zhao","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12885-022-09444-0","article-title":"Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials","volume":"22","author":"Zhao","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2026.104179_bib18","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.3390\/ijms23137222","article-title":"Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials","volume":"23","author":"de Scordilli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2026.104179_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial","volume":"39","author":"Zhong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.21.01729","article-title":"Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT)","volume":"40","author":"Tada","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib21","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104179_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1056\/NEJMoa2602628","article-title":"Selpercatinib in early-stage RET fusion-positive non-small-cell lung cancer","volume":"395","author":"Wu","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.104179_bib23","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.cllc.2018.04.004","article-title":"ADAURA: Phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection","volume":"19","author":"Wu","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.104179_bib24","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2026.44.16_suppl.8001","article-title":"Adjuvant erlotinib versus observation after complete resection of EGFR -mutant NSCLC: final overall survival results of Alliance A081105","volume":"44","author":"Govindan","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtho.2018.09.011","article-title":"Multimodal treatment in operable stage III NSCLC: a pooled analysis on long-term results of three SAKK trials (SAKK 16\/96, 16\/00, and 16\/01)","volume":"14","author":"Fr\u00fch","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104179_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12890-024-03138-y","article-title":"A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection","volume":"24","author":"Hu","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jtho.2026.104179_bib27","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.21037\/jtd-2024-2197","article-title":"Ten-year follow-up outcomes of resected stage II non-small cell lung cancer patients","volume":"17","author":"Sun","year":"2025","journal-title":"J Thorac Dis"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426006325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426006325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:06:35Z","timestamp":1791432395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426006325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"alternative-id":["S1556086426006325"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104179","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB\u2013IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"104179"}}